Inhibrx is a biologic immunotherapeutic company focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions.
Inhibrx LLC
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://inhibrx.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address11099 North Torrey Pines Road Suite 280,CA 092037La JollaUnited States
11099 North Torrey Pines Road Suite 280,CA 092037
La Jolla
United States
Contact Number+1 858 759 1499+1 858-568-7412
+1 858 759 1499
+1 858-568-7412
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/inhibrx” connections=”true” suffix=””]
Inhibrxs proprietary platforms enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation and mediate enhanced signaling.
In Aug 2012, Inhibrx out licence its first NBRX-103 antibody to Celgene Corp. in deal with potential value of $500 Mn, including up-front, clinical and regulatory milestone payments and royalties on commercial sales.
In July 2015, Inhibrx grants Five Prime Therapeutics exclusive, worldwide rights to develop and commercialize Inhibrxs preclinical glucocorticoid-induced tumor necrosis factor receptors (GITRs) antibody program. Under the terms, Five Prime paid $10 Mn up front and as much as $442.5 Mn in either cash or Five Prime stock, in undisclosed clinical, regulatory and sales milestones.